GeneOn advances two flagship programs—GOBT-101 and GOBT-201—built on the QUAI engine. We are open to global partnering structures including out-licensing, regional licensing, and co-development.
Positioning
This page summarizes how we package assets for licensing decisions: (1) clear MoA hypothesis, (2) preclinical readiness path, and (3) decision-grade evidence for partner diligence.
| Asset | Indication | Discovery | Lead Opt | Pre-clinical | Phase 1 | Status |
|---|---|---|---|---|---|---|
|
GOBT-101 LEAD |
Alopecia | GLP-Tox Ready | ||||
|
GOBT-201 NEW |
Sarcopenia | Hit-to-Lead |
Two programs, two design strategies—one engine. We tailor discovery and optimization strategy to disease context while keeping traceability and decision criteria consistent.
Lead Asset
Dual-action alopecia therapeutic peptide targeting the Androgen Receptor / DHT axis while supporting Wnt/β-catenin pathway activation.
MoA: AR blocking + Wnt/β-catenin activation
Value: Differentiated dual mechanism positioning
Partner fit: Dermatology / aesthetic / consumer-health
Expansion Pipeline
Next-generation expansion pipeline targeting sarcopenia through Apelin pathway modulation. First-in-class opportunity with no FDA-approved drugs.
MoA: Apelin pathway + mitochondrial biogenesis
Value: $3.2B market, 0 FDA-approved drugs
Partner fit: Metabolic / aging / chronic-care
QUAI is not “a single drug technology.” It switches design/optimization strategy by disease: AI→Quantum for GOBT-101 and Quantum→AI for GOBT-201.
Partner diligence requires decision-grade evidence: mechanism clarity, reproducible assay outcomes, and traceable optimization rationale.
We package assets with a clear path to IND-enabling: preclinical gates, risk map, and scalable CMC/clinical strategy alignment.
We structure deals based on partner capability, geography, and development stage.
• Global or regional rights
• Upfront + milestones + royalties
• Option for tech-transfer and joint diligence support
• Shared development plan (preclinical → clinical)
• Joint governance and data room
• Flexible cost-share / profit-share frameworks
• QUAI engine applied to partner targets
• Defined deliverables per stage-gate
• Option to convert to asset licensing
Typical partner questions we prepare for
Indication fit and differentiation, MoA evidence, preclinical reproducibility, safety plan, CMC feasibility, and development timeline assumptions (partner-specific).
A licensing discussion moves fastest when both sides align on data requirements and decision criteria early.
Execute NDA and share the initial asset summary pack.
Provide structured evidence: MoA, preclinical results, and planned next gates.
Partner technical diligence with Q&A and risk mapping.
Align on rights, territories, economics, and development responsibilities.
Finalize contract and (if applicable) tech transfer / joint development plan.
Clarity
MoA and differentiation framed for diligence
Speed
Data-room-ready evidence structure
Control
Stage-gated risk and decision criteria
If a partner requires additional validation layers prior to signing, we can package an optional “Partner Diligence Booster” using the services below.
For licensing discussions, please share your target territory, preferred partnering structure (license / co-dev), and the technical diligence focus areas (MoA, safety, CMC, clinical strategy). We will respond with a partner-ready information pack and a proposed diligence timeline.
If you have an internal diligence checklist, send it first—this page is designed to map cleanly to partner checklists.
ENGLISH
